triazoles has been researched along with Stroke in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YH; Liu, JG; Miao, CY; Qing, SL; Su, DF; Tian, JS; Wang, P; Wang, SN; Xu, JY; Xu, TY | 1 |
| Gao, A; Gao, J; Gao, L; Hu, Y; Li, J; Pang, T; Ruan, W; Xu, M; Ye, Q; Zhou, Y | 1 |
| Kawada, K; Miyamura, M; Ohta, T; Tanaka, K; Tanaka, S | 1 |
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Atasoylu, O; Bishop, T; Chan, MC; Chowdhury, R; Claridge, TD; Demetriades, M; Gómez-Pérez, V; Hodson, E; Holt-Martyn, J; Kawamura, A; Leung, IK; Pugh, CW; Ratcliffe, PJ; Rydzik, AM; Schofield, CJ; Tian, YM; Tumber, A | 1 |
| Chen, DY; Chen, TH; Cherng, WJ; Chou, CC; Hsieh, IC; Hung, KC; Lin, YS; Mao, CT; Su, FC; Tsai, ML; Wang, CC; Wang, SH; Wen, MS | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N | 1 |
| Digklia, A; Voutsadakis, IA | 1 |
| Kadaba, PK | 1 |
1 review(s) available for triazoles and Stroke
| Article | Year |
|---|---|
Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents.
Topics: Animals; Anticonvulsants; Brain Ischemia; Drug Design; Epilepsy; Humans; Pharmacokinetics; Stroke; Structure-Activity Relationship; Triazoles | 2003 |
5 trial(s) available for triazoles and Stroke
| Article | Year |
|---|---|
Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
Topics: Aged; Aged, 80 and over; Azepines; Delirium; Drug Therapy, Combination; Female; GABA Agonists; Humans; Indenes; Male; Orexin Receptor Antagonists; Receptors, Melatonin; Retrospective Studies; Risk Factors; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Stroke; Treatment Outcome; Triazoles | 2019 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2012 |
8 other study(ies) available for triazoles and Stroke
| Article | Year |
|---|---|
Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent.
Topics: Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Dogs; Electrocardiography; Female; Guinea Pigs; Heart Rate; Hypertension; Male; Molecular Docking Simulation; Rabbits; Rats, Inbred SHR; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha; Stroke; Thiazoles; Triazoles; Vasodilation; Vasodilator Agents | 2021 |
Synthesis and biological evaluation of novel 4,5-bisindolyl-1,2,4-triazol-3-ones as glycogen synthase kinase-3β inhibitors and neuroprotective agents.
Topics: Animals; Brain Ischemia; Computer Simulation; Glycogen Synthase Kinase 3 beta; In Vitro Techniques; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Stroke; Structure-Activity Relationship; Triazoles | 2017 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain.
Topics: Animals; Brain; Enzyme Inhibitors; HeLa Cells; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; MCF-7 Cells; Mice; Stroke; Triazoles | 2015 |
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2015 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |
Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Hemianopsia; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Stroke; Triazoles | 2012 |